Tango Therapeutics, Inc. (TNGX) Stock Grade

About Tango Therapeutics, Inc.'s fundamentals

Tango Therapeutics is a pre-profitability biotechnology company with a market capitalization of $1.0 billion that reported strong revenue growth of 48.3% year-over-year, indicating expanding commercial activity or advancing clinical programs. However, the company operates at a significant net loss with a net margin of -162.9%, meaning expenses substantially exceed revenues. The company does not currently pay a dividend and lacks positive return on equity, typical characteristics of early-stage biotech firms that prioritize research and development investment over near-term profitability.